EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis

Pedro Gomes Batista, Railla Raquel Albino Dos Santos Silva, Marcela Vasconcelos Montenegro, Mushrin Malik, Mrunalini Dandamudi, Juan Peres de Oliveira, Maria Eduarda Molinari, Larissa Araujo de Lucena, Ramon Huntermann, Juliana Giorgi, Caroline O Fischer Bacca

American Journal of Cardiovascular Drugs · 2026-09 · 26 (5) · 573-587

DOI: 10.1007/s40256-026-00809-5 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 01.07.2026. Verfasst von Pedro Gomes Batista und 10 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Paraíba, Campus I, Jardim Universitário, S/N, Castelo Branco - João Pessoa/PB, João Pessoa, PB, 58051-900, Brazil. pedro.batist…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Myocardial Infarction, Hypoglycemic Agents. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) who survive myocardial infarction (MI) remain at high risk for recurrent cardiovascular events and heart failure (HF). Although glucagon-like peptide-1 receptor agonist (GLP-1 RA) reduces cardiovascular events in stable atherosclerotic disease, its impact among patients with established MI has not been comprehensively synthesized. OBJECTIVES: To evaluate the association between GLP-1 RA use and cardiovascular outcomes in patients with T2DM across MI-defined cohorts. METHODS: We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Heterogeneity was evaluated using the I2 statistic, and 95% prediction intervals (PIs) were calculated to estimate the expected range of true effects in future clinical settings. Outcomes included all-cause mortality, cardiovascular death, study-defined major adverse cardiovascular events (MACE), MI, stroke, and HF or hospitalization for HF. A sensitivity analysis using the Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment was performed to account for the small number of included studies and substantial heterogeneity. Statistical analysis was performed using R software version 4.5.0. RESULTS: Seven studies, including 37,393 patients with T2DM from MI-defined populations (9556 receiving GLP-1 RA), were analyzed. GLP-1 RA use was associated with lower all-cause mortality (HR, 0.67; 95% CI, 0.49-0.90; I2 = 87.3%; PI, 0.27-1.63; P = 0.0085), reduced study-defined MACE (HR, 0.69; 95% CI, 0.56-0.84; I2 = 55.6%; PI, 0.44-1.06; P = 0.0002), and fewer HF events or hospitalizations for HF (HR, 0.78; 95% CI, 0.62-0.98; I2 = 77.6%; PI, 0.42-1.45; P = 0.0306). No significant associations were observed for cardiovascular death (HR, 0.85; 95% CI, 0.67-1.06; I2 = 0%; PI, 0.42-1.69; P = 0.15), recurrent MI (HR, 0.82; 95% CI, 0.62-1.09; I2 = 63%; PI, 0.41-1.63; P = 0.1753), or stroke (HR, 0.91; 95% CI, 0.68-1.22; I2 = 61.2%; PI, 0.40-2.05; P = 0.5237). In the sensitivity analysis using the HKSJ adjustment, statistical significance was lost for all endpoints, including all-cause mortality (P = 0.05), study-defined MACE (P = 0.13), and HF or hospitalization for HF (P = 0.06). CONCLUSIONS: In patients with T2DM across MI-defined populations, GLP-1 RA use showed signals toward lower all-cause mortality, study-defined MACE, and HF-related events; however, these findings remain exploratory because of substantial heterogeneity, wide PIs, and attenuation of statistical significance under HKSJ adjustment. REGISTRATION: PROSPERO identifier no. CRD420251270326.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsMyocardial InfarctionHypoglycemic AgentsHumansHeart FailureCardiovascular Diseases

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Federal University of Paraíba, Campus I, Jardim Universitário, S/N, Castelo Branco - João Pessoa/PB, João Pessoa, PB, 58051-900, Brazil. pedro.batista@academico.ufpb.br.
  • Federal University of Ceará, Fortaleza, CE, Brazil.
  • University of Pernambuco, Recife, PE, Brazil.
  • Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Montefiore Einstein Medical Center, Bronx, NY, USA.
  • University Center for the Development of Alto Vale, Rio do Sul, SC, Brazil.

Zitieren

APA

Batista, P. G., Dos Santos Silva, R. R. A., Montenegro, M. V., Malik, M., Dandamudi, M., de Oliveira, J. P., Molinari, M. E., de Lucena, L. A., Huntermann, R., Giorgi, J., & Bacca, C. O. F. (2026). GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 26(5), 573-587. https://doi.org/10.1007/s40256-026-00809-5

Vancouver

Batista PG, Dos Santos Silva RRA, Montenegro MV, Malik M, Dandamudi M, de Oliveira JP, et al. GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs. 2026;26(5):573-587. doi:10.1007/s40256-026-00809-5

BibTeX
@article{Batista2026,
  author = {Batista, Pedro Gomes and Dos Santos Silva, Railla Raquel Albino and Montenegro, Marcela Vasconcelos and Malik, Mushrin and Dandamudi, Mrunalini and de Oliveira, Juan Peres and Molinari, Maria Eduarda and de Lucena, Larissa Araujo and Huntermann, Ramon and Giorgi, Juliana and Bacca, Caroline O Fischer},
  title = {GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2026},
  volume = {26},
  number = {5},
  pages = {573--587},
  doi = {10.1007/s40256-026-00809-5}
}
Kostenlos starten →